| Adaptive Hypofractionated Radiotherapy for endometrial neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Adaptive Hypofractionated Radiotherapy for uterine cervical neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Adebelimab Combined with Apatinib for endometrial neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Adebrelimab for uterine cervical neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| AdHER2DC vaccine + PATHWAY HER2 (4B5) assay + Nogapendekin Alfa Inbakicept + PEMBROLIZUMAB + LENVATINIB for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| AdHER2DC vaccine + PATHWAY HER2 (4B5) assay + PEMBROLIZUMAB + LENVATINIB for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| AK105 and anlotinib for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Anti-PD-1 monoclonal antibody + LCB84 for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Anti-PD-1 monoclonal antibody + LCB84 for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| anti-PD1 agent therapy - 1 year for endometrial neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| anti-PD1 agent therapy - 2 years for endometrial neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Atezolizumab for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Avelumab for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Axitinib + AVELUMAB for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| AZD8205 and AZD2936 (Rilvegostomig) for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| AZD8205 and AZD5305 (saruparib) + AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig) for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| AZD8205 in combination with AZD9574 + AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936) for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Azenosertib for uterine neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| B1962 for uterine cervical neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| BEVACIZUMAB + PEMBROLIZUMAB + Izalontamab Brengitecan for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| BEVACIZUMAB + PEMBROLIZUMAB + Izalontamab Brengitecan for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Multigated Acquisition Scan + Radiologic Examination + OSIMERTINIB for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Multigated Acquisition Scan + Radiologic Examination + OSIMERTINIB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Radiologic Examination + Crizotinib for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Radiologic Examination + Crizotinib for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Echocardiography Test + Laboratory Biomarker Analysis + Radiologic Examination + PERTUZUMAB + TRASTUZUMAB for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Echocardiography Test + Laboratory Biomarker Analysis + Radiologic Examination + PERTUZUMAB + TRASTUZUMAB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| BNT329 for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| BNT329 + CA19-9-targeting monoclonal antibody for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Brachytherapy + External Beam Radiotherapy (EBRT) + NIMOTUZUMAB + CISPLATIN for uterine cervical neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Brachytherapy + External Beam Radiotherapy (EBRT) + placebo for Nimotuzumab + CISPLATIN for uterine cervical neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cadonilimab for uterine cervical neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cadonilimab + lenvatinib for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| camrelizumab; famitinib malate for uterine cervical neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| capecitabine or 5-FU + Intensity Modulated Radiation Therapy (IMRT) + DOSTARLIMAB for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Capivasertib for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Capivasertib for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin + NAB-PACLITAXEL for uterine cervical neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin + PEMBROLIZUMAB + CISPLATIN + Sigvotatug Vedotin for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin + PEMBROLIZUMAB + Sigvotatug Vedotin for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin-Paclitaxel for endometrial neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)] + CEMIPLIMAB + Ubletamig for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Chemotherapy + FAMITINIB L-MALATE + CAMRELIZUMAB for uterine cervical neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Chemotherapy + Hypofractionated external beam radiation + Image-guided brachytherapy for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| concurrent chemotherapy + Definitive hypofractionated intensity-modulated radiation theraphy for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| CR-002 for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ADAVOSERTIB for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ADAVOSERTIB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + AFATINIB + AFATINIB DIMALEATE for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + AFATINIB + AFATINIB DIMALEATE for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Binimetinib for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Binimetinib for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + CAPIVASERTIB for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + CAPIVASERTIB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + COPANLISIB HYDROCHLORIDE + COPANLISIB for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + COPANLISIB HYDROCHLORIDE + COPANLISIB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Crizotinib for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Crizotinib for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Dasatinib for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Dasatinib for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + DEFACTINIB + DEFACTINIB HYDROCHLORIDE for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + DEFACTINIB + DEFACTINIB HYDROCHLORIDE for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Fexagratinib for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Fexagratinib for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + GSK-2636771 for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + GSK-2636771 for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + IPATASERTIB for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + IPATASERTIB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB + RELATLIMAB for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB + RELATLIMAB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Palbociclib for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Palbociclib for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + SAPANISERTIB for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + SAPANISERTIB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TASELISIB for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TASELISIB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib + Dabrafenib Mesylate + DABRAFENIB for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib + Dabrafenib Mesylate + DABRAFENIB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TRASTUZUMAB + TRASTUZUMAB EMTANSINE for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TRASTUZUMAB + TRASTUZUMAB EMTANSINE for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ULIXERTINIB for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ULIXERTINIB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Daraxonrasib for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Dexamethasone + Prednisolone + FARLETUZUMAB ECTERIBULIN + Prednisone for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Diane-35 + N-METHYL-N-ETHYLTRYPTAMINE for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Dostarlimab for endometrial neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Dostarlimab-Gxly 50 MG/1 ML Intravenous Solution [JEMPERLI] for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Elironrasib for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Elironrasib + Daraxonrasib for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ETX-19477 for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Farletuzumab ecteribulin for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + Metformin + Tersolisib + Palbociclib + Exemestane + Ribociclib for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + Metformin + Tersolisib + Palbociclib + Exemestane + Ribociclib for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| FULVESTRANT + Tersolisib for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| FULVESTRANT + Tersolisib for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Gecacitinib + ZG005 + BEVACIZUMAB for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Glucagon-like peptide 1 receptor agonist for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GnRH agonist and Letrozole + Megestrol + MEDROXYPROGESTERONE for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GnRHa + Letrozole for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GT101 + HUMAN INTERLEUKIN-2 for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| High Dose Rate Brachytherapy + intra-lesional boost IMRT for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Iparomlimab and Tuvonralimab (QL1706) for endometrial neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| JSKN033 + BEVACIZUMAB + PLATINUM for uterine cervical neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| LCB84 for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| LCB84 for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Lenvatinib + farletuzumab ecteribulin for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Lorigerlimab for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + AFATINIB + AFATINIB DIMALEATE for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Sunitinib Malate for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Sunitinib Malate for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Vismodegib for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Vismodegib for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ERDAFITINIB for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ERDAFITINIB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + LAROTRECTINIB + LAROTRECTINIB SULFATE for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + LAROTRECTINIB + LAROTRECTINIB SULFATE for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Computed Tomography + Cytology Specimen Collection Procedure + COPANLISIB HYDROCHLORIDE + COPANLISIB for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Computed Tomography + Cytology Specimen Collection Procedure + COPANLISIB HYDROCHLORIDE + COPANLISIB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Mazdutide for endometrial neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Observation for endometrial neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Olaparib for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Olomorasib for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Olomorasib + PEMBROLIZUMAB + Cetuximab for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| OncoSignature + Prexasertib for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| OncoSignature + Prexasertib + Gemcitabine for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| paclitaxel combined with platinum for uterine cervical neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Patritumab Deruxtecan for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Patritumab Deruxtecan for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Pembrolizumab for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Pembrolizumab + nesuparib for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Pemetrexed + Carboplatin + Olomorasib + PEMBROLIZUMAB + Cetuximab + CISPLATIN for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Prexasertib for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Prexasertib + Gemcitabine for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Puxitatug Samrotecan for endometrial neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| radical surgery + CAMRELIZUMAB + Paclitaxel + CISPLATIN for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Rescue medications + Sacituzumab tirumotecan for endometrial neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sacituzumab + cisplatin for uterine neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sacituzumab govitecan for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sacituzumab govitecan for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Sacituzumab tirumotecan for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sacituzumab tirumotecan for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Serplulimab for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| SHR-A1811 Injection for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sigvotatug Vedotin for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sintilimab for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| SINTILIMAB + Megestrol + MEDROXYPROGESTERONE for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sirolimus for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Spartalizumab for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Talazoparib + avelumab for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| TAMOXIFEN + FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + IMLUNESTRANT + Tersolisib + Palbociclib + Exemestane + Ribociclib for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| TAMOXIFEN + FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + IMLUNESTRANT + Tersolisib + Palbociclib + Exemestane + Ribociclib for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tersolisib for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tersolisib for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| TH BSO with SNB Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted for endometrial neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tislelizumab for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Topotecan + toripalimab for endometrial neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Trastuzumab deruxtecan for endometrial neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| TRASTUZUMAB DERUXTECAN + Rilvegostomig for endometrial neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tretinoin for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tretinoin for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| UBAMATAMAB + Ubletamig + SARILUMAB for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| VLS-1488 for endometrial neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Vudalimab for endometrial neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Vudalimab for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|